Placeholder Banner

BIO Welcomes John Delacourt as Deputy General Counsel

March 15, 2023
Media Contact
Karen Batra

Mr. Delacourt is a senior litigator and regulatory counselor with more than a decade of experience advising biotech companies

WASHINGTON – (March 15, 2023) – The Biotechnology Innovation Organization (BIO) welcomes John Delacourt as Deputy General Counsel – VP Health, Regulatory, and Commercial Operations. John will work with BIO’s staff to lead legal support for commercial operations and with its membership to ensure patient access to life-saving medicines, bring down barriers to innovation, and promote policies conducive to advances in agriculture and environmental science.

 John comes to BIO from another biotech trade group – the Plasma Protein Therapeutics Association (PPTA) – where he served as Chief Legal Officer & Head of Global Policy. While at PPTA, John led the association’s litigation defense and regulatory compliance efforts in both the United States and Europe. He also served as legal advisor to PPTA’s principal governing bodies, including on such issues as drug shortage preparedness, discriminatory labeling practices, and secure handling of biometric data.

Prior to joining PPTA, John practiced at major law firms in Washington, D.C. and New York. He also served in senior roles at the Federal Trade Commission, including as Chief Antitrust Counsel of the FTC’s Office of Policy Planning.

“John’s healthcare and compliance experience make him a welcome addition to our growing legal team,” said Chief Legal Officer Peter McHugh. “As BIO continues to address the legal challenges presented by the Inflation Reduction Act, advocate for efficient market access for innovative products, and support a favorable environment for biotech investment, we are excited to have John on our side.”

John is a graduate of Georgetown University and Harvard Law School.

Discover More
Representatives John Joyce, M.D. (R-PA) and Wiley Nickel (D-NC) today introduced the Optimizing Research Progress Hope And New Cures (ORPHAN Cures Act). BIO President and CEO, Rachel King, made the following remarks: "This legislation is a welcome…
The Biotechnology Innovation Organization has honored two biotechnology leaders who are driving cutting-edge breakthroughs in agricultural, environmental and industrial biotechnology. Dr. Pam Marrone, Co-founder and Executive Chair of Invasive…
Yesterday the Federal Trade Commission (FTC) announced the decision to settle its Amgen-Horizon merger challenge. The settlement will give the Commission the relief it needs to protect competition, while allowing rare disease patients to enjoy the…